Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-amino-modified KRAS-G12D neoantigen peptide
- Development stage
- Preclinical
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Peptides
01
Overview
N-amino-modified KRAS-G12D neoantigen peptide is a preclinical peptide therapeutic designed to stabilize the conformation of the KRAS-G12D mutant peptide when presented by human leukocyte antigen (HLA) class I (specifically HLA-A11). Developed by researchers at the University of Notre Dame and Memorial Sloan Kettering Cancer Center, this modified peptide aims to pre-pay the entropic penalty associated with T-cell receptor (TCR) binding. By enhancing TCR recognition and binding affinity, the peptide serves as a potential superagonist to advance T cell-based immunotherapies and cancer vaccines targeting KRAS-G12D-mutant cancers.
- Other names
- N-amino-modified KRAS peptidesN-amino-modified KRAS-G12D peptide
02
Targets
KRAS (Kirsten rat sarcoma viral oncogene homolog)HLA-A (HLA class I histocompatibility antigen A alpha chain)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on N-amino-modified KRAS-G12D neoantigen peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-amino-modified KRAS-G12D neoantigen peptide.